Edwards Lifesciences Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 6 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences or view top-rated stocks.

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, October 20th 2021.
View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Thursday, July, 29th. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.09. The medical research company earned $1.38 billion during the quarter, compared to the consensus estimate of $1.29 billion. Edwards Lifesciences had a net margin of 29.69% and a trailing twelve-month return on equity of 29.73%.
View Edwards Lifesciences' earnings history.

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EW stock has increased by 83.4% and is now trading at $120.69.
View which stocks have been most impacted by COVID-19.

Edwards Lifesciences's stock split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its third quarter 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of $0.500-$0.560 for the period, compared to the Thomson Reuters consensus estimate of $0.550. The company issued revenue guidance of $1.29 billion-$1.37 billion, compared to the consensus revenue estimate of $1.30 billion.

18 brokerages have issued 1-year price objectives for Edwards Lifesciences' shares. Their forecasts range from $85.00 to $135.00. On average, they expect Edwards Lifesciences' stock price to reach $118.44 in the next twelve months. This suggests that the stock has a possible downside of 1.9%.
View analysts' price targets for Edwards Lifesciences or view top-rated stocks among Wall Street analysts.

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of EW's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.48%), Vanguard Group Inc. (7.75%), State Street Corp (4.13%), Bank of New York Mellon Corp (3.75%), Capital International Investors (3.21%) and Alliancebernstein L.P. (2.09%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jackson Square Partners LLC, Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Neuberger Berman Group LLC, Sumitomo Mitsui Trust Holdings Inc., Great West Life Assurance Co. Can, and AQR Capital Management LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences or view top insider-selling stocks.

EW stock was acquired by a variety of institutional investors in the last quarter, including Amundi, FMR LLC, First Trust Advisors LP, Capital International Investors, 1832 Asset Management L.P., Man Group plc, UBS Asset Management Americas Inc., and Lord Abbett & CO. LLC.
View insider buying and selling activity for Edwards Lifesciences or or view top insider-buying stocks.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $120.69.

Edwards Lifesciences has a market capitalization of $75.23 billion and generates $4.39 billion in revenue each year. The medical research company earns $823.40 million in net income (profit) each year or $1.86 on an earnings per share basis.

Edwards Lifesciences employs 14,900 workers across the globe.

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

Edwards Lifesciences was founded in 1958.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at (949) 250-2500 or via email at [email protected]